Chemomab Therapeutics Announces Late-Breaking Oral Presentation of CM-101 Phase 2 Results in Primary Sclerosing Cholangitis at AASLD The Liver Meeting® 2024
Chemomab Therapeutics (Nasdaq: CMMB) announced that its late-breaking abstract on the Phase 2 SPRING trial results for CM-101 in primary sclerosing cholangitis (PSC) has been selected for an oral presentation at the AASLD The Liver Meeting® 2024. The conference will be held in San Diego from November 15-19, 2024.
Professor Christopher Bowlus, MD, FAASLD, from the University of California Davis School of Medicine, will present the data from the double-blinded portion of the trial. The presentation, titled 'CM-101 improved fibrosis biomarkers in patients with primary sclerosing cholangitis: The Phase 2 SPRING Study', is scheduled for November 18, 2024, from 2:45-3:00pm PT during the Late Breaking Abstract Parallel Session 1.
Chemomab Therapeutics (Nasdaq: CMMB) ha annunciato che il suo abstract a presentazione tardiva sui risultati del trial di Fase 2 SPRING per CM-101 nella colangite sclerosante primaria (PSC) è stato selezionato per una presentazione orale al AASLD The Liver Meeting® 2024. La conferenza si terrà a San Diego dal 15 al 19 novembre 2024.
Il Professore Christopher Bowlus, MD, FAASLD, dell'Università della California Davis School of Medicine, presenterà i dati della parte a doppio cieco dello studio. La presentazione, intitolata 'CM-101 ha migliorato i biomarcatori della fibrosi nei pazienti con colangite sclerosante primaria: Lo Studio di Fase 2 SPRING', è programmata per il 18 novembre 2024, dalle 14:45 alle 15:00 PT durante la Sessione Parallela degli Abstract a Presentazione Tardiva 1.
Chemomab Therapeutics (Nasdaq: CMMB) anunció que su resumen de presentación tardía sobre los resultados del ensayo de Fase 2 SPRING para CM-101 en colangitis esclerosante primaria (PSC) ha sido seleccionado para una presentación oral en el AASLD The Liver Meeting® 2024. La conferencia se llevará a cabo en San Diego del 15 al 19 de noviembre de 2024.
El Profesor Christopher Bowlus, MD, FAASLD, de la Universidad de California Davis School of Medicine, presentará los datos de la parte a doble ciego del ensayo. La presentación, titulada 'CM-101 mejoró los biomarcadores de fibrosis en pacientes con colangitis esclerosante primaria: El Estudio de Fase 2 SPRING', está programada para el 18 de noviembre de 2024, de 2:45 a 3:00 pm PT durante la Sesión Paralela de Resúmenes de Presentación Tardía 1.
Chemomab Therapeutics (Nasdaq: CMMB)는 CM-101의 2상 SPRING 시험 결과에 대한 발제 내용이 주요 담석 담낭 염(PBC)에 대한 구두 발표로 AASLD The Liver Meeting® 2024에 선정되었음을 발표했습니다. 이 회의는 2024년 11월 15일부터 19일까지 샌디에이고에서 개최됩니다.
캘리포니아 대학교 데이비스 의과대학의 크리스토퍼 볼루스 교수(MD, FAASLD)가 시험의 이중 맹검 부분에서 데이터를 발표할 예정입니다. 'CM-101가 주요 담석 담낭 염 환자의 섬유증 바이오마커를 개선했습니다: 2상 SPRING 연구'라는 제목의 발표는 2024년 11월 18일 오후 2시 45분부터 3시까지 PT로 예정되어 있으며, 발표가 늦게 진행되는 추상 세션 1에서 이루어질 것입니다.
Chemomab Therapeutics (Nasdaq: CMMB) a annoncé que son résumé à présentation tardive sur les résultats de l'
Le professeur Christopher Bowlus, MD, FAASLD, de l'école de médecine de l'université de Californie à Davis, présentera les données de la partie à double insu de l'essai. La présentation, intitulée 'Le CM-101 a amélioré les biomarqueurs de fibrose chez les patients atteints de cholangite sclérosante primitive : l'étude de Phase 2 SPRING', est prévue pour le 18 novembre 2024, de 14h45 à 15h00 PT pendant la session parallèle sur les résumés à présentation tardive 1.
Chemomab Therapeutics (Nasdaq: CMMB) gab bekannt, dass ihr Late-Breaking-Abstract zu den Ergebnissen der Phase 2 SPRING-Studie für CM-101 bei primärer sklerosierender Cholangitis (PSC) für eine mündliche Präsentation auf dem AASLD The Liver Meeting® 2024 ausgewählt wurde. Die Konferenz findet vom 15. bis 19. November 2024 in San Diego statt.
Professor Christopher Bowlus, MD, FAASLD, von der University of California Davis School of Medicine, wird die Daten des doppelblinden Teils der Studie präsentieren. Die Präsentation mit dem Titel 'CM-101 verbesserte Fibrose-Biomarker bei Patienten mit primär sklerosierender Cholangitis: Die Phase 2 SPRING-Studie' ist für den 18. November 2024, von 14:45 bis 15:00 Uhr PT, während der Late Breaking Abstract Parallel Session 1 geplant.
- Phase 2 SPRING trial results selected for late-breaking oral presentation at AASLD The Liver Meeting® 2024
- CM-101 showed improvement in fibrosis biomarkers in PSC patients
- None.
TEL AVIV, Israel, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that its late breaking abstract discussing the results of the Phase 2 SPRING trial in primary sclerosing cholangitis (PSC) has been selected for an oral presentation at the American Association for the Study of Liver Disease (AASLD) The Liver Meeting® 2024. The conference will take place in San Diego, California, November 15 – 19, 2024.
Professor Christopher Bowlus, MD, FAASLD, the Lena Valente Professor and Chief of the Division of Gastroenterology and Hepatology at the University of California Davis School of Medicine will give an oral presentation describing data from the double-blinded portion of the Phase 2 SPRING trial assessing CM-101 in individuals with PSC.
Title: CM-101 improved fibrosis biomarkers in patients with primary sclerosing cholangitis: The Phase 2 SPRING Study
Author: Christopher Bowlus, MD
Session: Late Breaking Abstract Parallel Session 1
Session Time: November 18, 2024, 2:00pm – 3:30pm PDT
Presentation Time: November 18, 2024, 2:45 - 3:00pm PT
Publication Number: 5005
Members of the Chemomab senior leadership team will be attending the 2024 AASLD conference. Please reach out to set up a meeting or to learn more about the company.
About Chemomab Therapeutics Ltd.
Chemomab is a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. Based on the unique role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a dual activity monoclonal antibody that neutralizes CCL24 activity. In clinical and preclinical studies, CM-101 has been shown to have a favorable safety profile and has been generally well-tolerated, with the potential to treat multiple severe and life-threatening fibro-inflammatory diseases. Chemomab has reported positive results from four clinical trials of CM-101 in patients. Based on recent promising data from its Phase 2 trial in the rare liver disease primary sclerosing cholangitis (PSC), the company expects two upcoming milestones in early 2025, including FDA feedback on the design of its planned PSC Phase 3 registrational trial. CM-101 has received FDA and EMA Orphan Drug and FDA Fast Track designations for PSC. Chemomab’s CM-101 program for the treatment of systemic sclerosis is Phase 2-ready with an open U.S. IND. For more information, visit www.chemomab.com.
Contacts:
Media and Investors:
Barbara Lindheim
Consulting Vice President, Investor & Public Relations, Strategic Communications
Phone: +1 917-355-9234
barbara.lindheim@chemomab.com
IR@chemomab.com
FAQ
What are the key findings of Chemomab's Phase 2 SPRING trial for CM-101 in PSC (CMMB)?
When and where will Chemomab's Phase 2 SPRING trial results for CM-101 (CMMB) be presented?
Who will present Chemomab's Phase 2 SPRING trial results for CM-101 in PSC (CMMB)?
What is the title of Chemomab's presentation on CM-101 Phase 2 results (CMMB)?
